Similar articles

• [Efficacy and safety of stimulants and non-stimulants in adults with attention deficit hyperactivity disorder (ADHD)].

  Golubchik P, Sever J, Weizman A. Golubchik P, et al. Harefuah. 2011 Oct;150(10):788-90, 814. Harefuah. 2011. PMID: 22111124 Review. Hebrew.
• Differences in Utilization Patterns among Medications in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: a 36-Month Retrospective Study Using the Korean Health Insurance Review and Assessment Claims Database.

  Bhang SY, Hwang JW, Kwak YS, Joung YS, Lee S, Kim B, Sohn SH, Chung US, Yang J, Hong M, Bahn GH, Choi HY, Oh IH, Lee YJ. Bhang SY, et al. J Korean Med Sci. 2016 Aug;31(8):1284-91. doi: 10.3346/jkms.2016.31.8.1284. Epub 2016 Jun 7. J Korean Med Sci. 2016. PMID: 27478341 Free PMC article.
• An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Children with Attention-Deficit/Hyperactivity Disorder.

  Shang CY, Pan YL, Lin HY, Huang LW, Gau SS. Shang CY, et al. J Child Adolesc Psychopharmacol. 2015 Sep;25(7):566-73. doi: 10.1089/cap.2015.0035. Epub 2015 Jul 29. J Child Adolesc Psychopharmacol. 2015. PMID: 26222447 Clinical Trial.
• ADHD medication adherence: the importance of adequate prescribing.

  Vertessen K, Luman M, Oosterlaan J. Vertessen K, et al. Lancet Psychiatry. 2024 Jan;11(1):2-3. doi: 10.1016/S2215-0366(23)00393-0. Epub 2023 Nov 27. Lancet Psychiatry. 2024. PMID: 38035875 No abstract available.
• [Attention deficit disorder with hyperactivity (ADHD). Continuing symptom control with medium term methylphenidate treatment].

  Oberpichler-Schwenk H. Oberpichler-Schwenk H. Med Monatsschr Pharm. 2006 Nov;29(11):415-6. Med Monatsschr Pharm. 2006. PMID: 17131689 Review. German. No abstract available.